Giovanni Donadoni

发表

Cancer Therapy : Clinical Phase I Study of NGR-hTNF , a Selective Vascular Targeting Agent , in Combination with Cisplatin in Refractory Solid Tumors

Roberto Scalamogna, Vanesa Gregorc, C. Bordignon, 2011 .

Phase I Study of NGR-hTNF, a Selective Vascular Targeting Agent, in Combination with Cisplatin in Refractory Solid Tumors

Roberto Scalamogna, Vanesa Gregorc, F. D. De Braud, 2011, Clinical Cancer Research.